0000203077 2009-04-05 2009-07-04 0000203077 stj:AdjustedNewAccountingTreatmentMember 2008-03-30 2008-06-28 0000203077 2007-12-30 2009-01-03 0000203077 stj:AdjustedNewAccountingTreatmentMember 2008-06-28 0000203077 stj:AdjustedNewAccountingTreatmentMember 2007-12-29 0000203077 stj:AdjustedNewAccountingTreatmentMember 2007-12-30 2008-06-28 0000203077 2009-07-04 0000203077 2009-01-03 0000203077 2008-06-27 0000203077 2009-07-30 0000203077 2009-01-04 2009-07-04 iso4217:USD xbrli:shares xbrli:shares iso4217:USD

<html> <head></head> <body>  <div style="font-family: 'Times New Roman',Times,serif">  <div align="center" style="font-size: 10pt; margin-top: 0pt"><b> <div align="left"> </div> </b> </div> <div align="left"> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>NOTE 1 — BASIS OF PRESENTATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The accompanying unaudited condensed consolidated financial statements of St. Jude Medical, Inc. (St. Jude Medical or the Company) have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, these statements include all adjustments (consisting of normal recurring adjustments) considered necessary to present a fair statement of the Company’s consolidated results of operations, financial position and cash flows. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. Preparation of the Company’s financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts in the financial statements and footnotes. Actual results could differ from those estimates. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and footnotes included in its Annual Report on Form 10-K for the fiscal year ended January 3, 2009 (2008 Annual Report on Form 10-K), as revised by its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 22, 2009 to reflect the retrospective impact of the adoption of Financial Accounting Standards Board (FASB) Staff Position (FSP) Accounting Principles Board (APB) Opinion No. 14-1, <i>Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement) </i>(FSP APB No. 14-1). All prior periods presented in this Quarterly Report on Form 10-Q have been retrospectively adjusted for the impact of the adoption of FSP APB No. 14-1 (see Note 3). </div> <div align="left"> </div> </div> </body> </html>

<html> <head></head> <body>  <div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>NOTE 2 — NEW ACCOUNTING PRONOUNCEMENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In April 2009, the FASB issued two related FSPs: (i) FSP SFAS No. 115-2 and SFAS No. 124-2, <i>Recognition of Presentation of Other-Than-Temporary Impairments </i>(FSP SFAS No. 115-2/SFAS No. 124-2) and (ii) FSP SFAS No. 107-1 and APB Opinion No. 28-1, <i>Interim Disclosures about Fair Value of Financial Instruments </i>(FSP SFAS No. 107-1/APB No. 28-1), which are effective for interim and annual reporting periods ending after June 15, 2009. FSP SFAS No. 115-2/SFAS No. 124-2 modifies the requirement for recognizing other-than-temporary impairments, changes the existing impairment model, and modifies the presentation and frequency of related disclosures. FSP SFAS No. 107-1/APB No. 28-1 requires fair value disclosures at interim reporting periods for financial instruments not reflected in the Condensed Consolidated Balance Sheets at fair value, which are similar to the fair value disclosures required in annual financial statements for those same assets and liabilities. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In May 2009, the FASB issued Statement of Financial Accounting Standards (SFAS) No. 165, <i>Subsequent Events </i>(SFAS No. 165), which establishes general standards of accounting for and disclosures of events that occur after the balance sheet date but before the financial statements are issued or available to be issued. It requires the disclosure of the date through which the Company has evaluated its subsequent events and the basis for that date. The Company has evaluated its subsequent events through August 12, 2009, the date of issuance of this Quarterly Report on Form 10-Q (see Note 15). </div> <div align="left"> </div> </div> </body> </html>

<html> <head></head> <body>  <div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>NOTE 7 – COMMITMENTS AND CONTINGENCIES</b>   </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>Litigation</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">  The Company accrues a liability for costs related to claims, including future legal costs, settlements and judgments, where it has assessed that a loss is probable and an amount can be reasonably estimated. The Company also records a receivable from its product liability insurance carriers for amounts expected to be recovered.  <br /> <br style="font-size: 6pt" /> <i>Silzone® Litigation and Insurance Receivables</i>:  The Company has been sued in various jurisdictions beginning in March 2000 by some patients who received a product with Silzone® coating, and such cases are pending in the United States and Canada. Some of these claimants allege bodily injuries as a result of an explant or other complications, which they attribute to Silzone®-coated products. Others, who have not had their Silzone®-coated heart valve explanted, seek compensation for past and future costs of special monitoring they allege they need over and above the medical monitoring all other replacement heart valve patients receive. Some of the lawsuits seeking the cost of monitoring have been initiated by patients who are asymptomatic and who have no apparent clinical injury to date. The Company has vigorously defended against the claims that have been asserted and expects to continue to do so with respect to any remaining claims.   </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In 2001, the U.S. Judicial Panel on Multi-District Litigation (MDL) ruled that certain lawsuits filed in U.S. federal district court involving products with Silzone® coating should be part of MDL proceedings in the U.S. District Court in Minnesota (the District Court). As a result, actions in federal court involving products with Silzone® coating have been and will likely continue to be transferred to the District Court for coordinated or consolidated pretrial proceedings.   <br /> <br style="font-size: 6pt" /> In October 2001, various class-action complaints were consolidated into one class action case by the District Court. The Company requested the Eighth Circuit Court of Appeals (the Eighth Circuit) to review the District Court’s initial class certification orders and, in October 2005, the Eighth Circuit issued a decision reversing the District Court’s class certification rulings and directed the District Court to undertake further proceedings. In October 2006, the District Court granted plaintiffs’ renewed motion to certify a nationwide consumer protection class under Minnesota’s consumer protection statutes and Private Attorney General Act. The Company again requested the Eighth Circuit to review the District Court’s class certification orders and, in April 2008, the Eighth Circuit again issued a decision reversing the District Court’s October 2006 class certification rulings. The order by the Eighth Circuit returned the case to the District Court for continued proceedings. The plaintiffs requested the District Court to certify a new class, but on June 23, 2009, the District Court issued an order striking any remaining claims seeking class action status. As a result, the former class representative has only an individual claim at the present time. The Company will continue to vigorously defend against this and other Silzone claims. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">There are five individual Silzone® cases pending in federal court. The plaintiffs in these cases are requesting damages in excess of $75 thousand. The complaint in the case that was most recently transferred to the MDL court was served upon the Company in December 2008. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">There are seven individual state court suits concerning Silzone®-coated products pending, involving seven patients. These cases are venued in Minnesota and Texas. The complaints in these state court cases are requesting damages ranging from $10 thousand to $100 thousand and, in some cases, seek an unspecified amount. The most recent individual state court complaint was served upon the Company in February 2008. These state court cases are proceeding in accordance with the orders issued by the judges in those matters.  </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In Canada, there are also four class-action cases and one individual case pending against the Company. In one such case in Ontario, the court certified that a class action involving Silzone® patients may proceed, and the trial of the initial phase of this matter is expected to occur as early as September 2009. A second case seeking class action status in Ontario has been stayed pending resolution of the other Ontario class action. A case filed as a class action in British Columbia remains pending. A court in Quebec has certified a class action, and that matter is proceeding in accordance with that court’s orders. Additionally, the Company has been served with lawsuits by the British Columbia Provincial health insurer and the Quebec Provincial health insurer to recover the cost of insured services furnished or to be furnished to class members in the class actions pending in British Columbia and Quebec, respectively. The complaints in the Canadian cases request damages ranging from 1.5 million to 2.0 billion Canadian Dollars (the equivalent to $1.3 million to $1.7 billion at July 4, 2009).  <br /> <br style="font-size: 6pt" /> The Company is not aware of any unasserted claims related to Silzone®-coated products. Company management believes that the final resolution of the Silzone® cases will take a number of years.  <br /> <br style="font-size: 6pt" /> The Company has recorded an accrual for probable legal costs that it will incur to defend the various cases involving Silzone®-coated products, and the Company has recorded a receivable from its product liability insurance carriers for amounts expected to be recovered. The Company has not accrued for any amounts associated with settlements or judgments because potential losses cannot be reasonably estimated. Based on the Company’s experience in these types of individual cases, the amount ultimately paid, if any, often does not bear any relationship to the amount claimed by the plaintiffs and is often significantly less than the amount claimed. Any costs (the material components of which are settlements, judgments, legal fees and other related defense costs) not covered by the Company’s product liability insurance policies or existing reserves could be material to the Company’s consolidated earnings, financial position and cash flows. As of July 4, 2009, the Company’s Silzone® litigation reserve was $23.1 million and the related receivable from insurance carriers was $21.6 million. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company’s remaining product liability insurance for Silzone® claims consists of two $50.0 million layers, each of which is covered by one or more insurance companies. The first $50.0 million layer of insurance is covered by American Insurance Company (AIC). In December 2007, AIC initiated a lawsuit in Minnesota Federal District Court seeking a court order declaring that it is not required to provide coverage for a portion of the Silzone® litigation defense and indemnity expenses that the Company may incur in the future. The Company believes the claims of AIC are without merit and plans to vigorously defend against the claims AIC has asserted. The insurance broker that assisted the Company in procuring the insurance with AIC has been added as a party to the case. For all Silzone® legal costs incurred, the Company records insurance receivables for the amounts that it expects to recover.   </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Part of the Company’s final layer of insurance ($20.0 million of the final $50.0 million layer) is covered by Lumberman’s Mutual Casualty Insurance, a unit of the Kemper Insurance Companies (collectively referred to as Kemper). Prior to being no longer rated by A.M. Best, Kemper’s financial strength rating was downgraded to a “D” (poor). Kemper is currently in “run off,” which means it is no longer issuing new policies, and therefore, is not generating any new revenue that could be used to cover claims made under previously-issued policies. In the event Kemper is unable to pay claims directed to it, the Company believes the other insurance carriers in the final layer of insurance will take the position that the Company will be directly liable for any claims and costs that Kemper is unable to pay. It is possible that Silzone® costs and expenses will reach the limit of the final Kemper layer of insurance coverage, and it is possible that Kemper will be unable to meet its full obligations to the Company. Therefore, the Company could incur an expense up to $20.0 million for which it would have otherwise been covered. While potential losses are possible, the Company has not accrued for any such losses as they are not reasonably estimable at this time.  <br /><br style="font-size: 6pt" /> <i>Guidant 1996 Patent Litigation</i>:  In November 1996, Guidant Corporation (Guidant), which became a subsidiary of Boston Scientific Corporation in 2006, sued the Company in federal district court for the Southern District of Indiana alleging that the Company did not have a license to certain patents controlled by Guidant covering tachycardia implantable cardioverter defibrillator systems (ICDs) and alleging that the Company was infringing those patents.  <br /><br style="font-size: 6pt" /> Guidant’s original suit alleged infringement of four patents by the Company. Guidant later dismissed its claim on the first patent and the district court ruled that the second patent was invalid, and this ruling was later upheld by the Court of Appeals for the Federal Circuit (CAFC). The third patent was found to be invalid by the district court. The fourth patent (the ‘288 patent) was initially found to be invalid by the district court judge, but the CAFC reversed this decision in August 2004. The case was returned to the district court in November 2004. The district court issued rulings on claims construction and a response to motions for summary judgment in March 2006. Guidant’s special request to appeal certain aspects of these rulings was rejected by the CAFC. In March 2007, the district court judge responsible for the case granted summary judgment in favor of the Company, ruling that the only remaining patent claim (the ‘288 patent) asserted against the Company in the case was invalid. In April 2007, Guidant appealed the district court’s March 2007 and March 2006 rulings. In December 2008, the CAFC upheld the March 2006 rulings of the district court but also reversed the district court’s March 2007 ruling that the ‘288 patent was invalid. As such, based on that ruling, although the invalidity of the ‘288 patent was overturned, the damages in the case going forward are limited to those relatively few instances prior to the expiration of the patent in 2003 when the cardioversion therapy method described in the only remaining claim of the ‘288 patent is actually practiced. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The parties filed requests with the CAFC requesting that the entire CAFC re-hear some of the issues addressed in the December 2008 decision, and the CAFC issued a ruling in March 2009 vacating its December 2008 decision, denying Guidant’s request for re-hearing and granting part of the Company’s request for re-hearing. Oral arguments occurred in May 2009 on the one issue the CACF asked the parties to brief, and the parties are presently awaiting a decision from the CAFC.  <br /> <br style="font-size: 6pt" /> The ‘288 patent expired in December 2003. Accordingly, the final outcome of the litigation involving the ‘288 patent cannot result in an injunction precluding the Company from selling ICD products in the future. Sales of the Company’s ICD products in which Guidant asserts infringement of the ‘288 patent were approximately 18% and 16% of the Company’s consolidated net sales during fiscal years 2003 and 2002, respectively. Additionally, based on a July 2006 agreement, in exchange for the Company’s agreement not to pursue the recovery of attorneys’ fees or assert certain claims and defenses, Guidant agreed it would not seek recovery of lost profits, prejudgment interest or a royalty rate in excess of 3% of net sales for any patents found to be infringed upon by the Company. This agreement had the effect of limiting the Company’s financial exposure. Based on this and the recent rulings in this case, the Company does not believe that any potential losses arising from any legal settlements or judgments in this case could be material to the Company’s consolidated earnings, financial position and cash flows. The Company has not accrued any amounts for legal settlements or judgments related to the Guidant 1996 patent litigation. Although the Company believes that the assertions and claims in the Guidant 1996 patent litigation are without merit, potential losses arising from any legal settlements or judgments are possible, but not reasonably estimable at this time. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"><i>Ohio OIG Investigation</i>:  In July 2007, the Company received a civil subpoena from the U.S. Department of Health and Human Services, Office of the Inspector General (OIG), requesting documents regarding the Company’s relationships with ten Ohio hospitals during the period from 2003 through 2006. The Company has received follow-up requests from the U.S. Department of Justice and the U.S. Attorney’s Office in Cleveland regarding this matter. The Company is cooperating with the investigation and is continuing to work with the OIG in responding to the subpoena.  <br /> <br style="font-size: 6pt" /> <i>Boston U.S. Attorney Investigation</i>:  In October 2005, the U.S. Department of Justice, acting through the U.S. Attorney’s office in Boston, commenced an industry-wide investigation into whether the provision of payments and/or services by makers of ICDs and bradycardia pacemaker systems (pacemakers) to doctors or other persons constitutes improper inducements under the federal health care program anti-kickback law. As part of this investigation, the Company received a civil subpoena from the U.S. Attorney’s office in Boston requesting documents created since January 2000 regarding the Company’s practices related to ICDs, pacemakers, lead systems and related products marketed by the Company’s Cardiac Rhythm Management segment. The Company understands that its principal competitors in the cardiac rhythm management therapy areas received similar civil subpoenas. The Company received an additional subpoena from the U.S. Attorney’s office in Boston in September 2006, requesting documents created since January 2002 related to certain employee expense reports and certain ICD and pacemaker purchasing arrangements. The Company is cooperating with the investigation and has been producing documents and witnesses as requested. In December 2008, the U.S. Attorney’s Office in Boston delivered a third subpoena issued by the Department of Health & Human Services Office of Inspector General requesting the production of documents relating to implantable cardiac rhythm device and pacemaker warranty claims. The Company is cooperating with these investigations. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"><i>U.S. Department of Justice Investigation</i>: In October 2008, the Company received a letter from the Civil Division of the U.S. Department of Justice stating that it was investigating the Company for potential False Claims Act and common law violations relating to the sale of the Company’s Epicor<sup style="font-size: 85%; vertical-align: text-top">TM</sup> surgical ablation devices. The Department of Justice is investigating whether companies marketed surgical ablation devices for off-label treatment of atrial fibrillation. Other manufacturers of medical devices used in the treatment of atrial fibrillation have reported receiving similar letters. The letter requests that we provide documents from January 1, 2005 to present relating to U.S. Food and Drug Administration (FDA) approval and marketing of Epicor<sup style="font-size: 85%; vertical-align: text-top">TM</sup> ablation devices. The Company is cooperating with the investigation. In July 2009, the U.S. District Court in Houston, Texas unsealed a false claims suit against the Company. Similar suits were unsealed at the same time against other manufacturers of surgical ablation devices. The Department of Justice has not decided whether to intervene in the suit against the Company.  <br /> <br style="font-size: 6pt" /> <i>Securities Class Action Litigation</i>:  In April and May 2006, five shareholders, each purporting to act on behalf of a class of purchasers during the period January 25 through April 4, 2006 (the Class Period), separately sued the Company and certain of its officers in federal district court in Minnesota alleging that the Company made materially false and misleading statements during the Class Period relating to financial performance, projected earnings guidance and projected sales of ICDs. The complaints, all of which seek unspecified damages and other relief, as well as attorneys’ fees, have been consolidated. The Company filed a motion to dismiss, which was denied by the district court in March 2007. The discovery process concluded in September, and the Company filed a motion for summary judgment which was argued before the Court in January 2009. In June 2009, the Court issued its ruling granting summary judgment in favor of the Company on all claims. The plaintiffs have agreed not to appeal this matter, to pay the Company certain costs and fees and to provide a full release of all claims asserted in the action or that could have been asserted against the Company and the individual defendants.  <br /> <br style="font-size: 6pt" /> <i>Derivative Action</i>: In February 2007, a derivative action was filed in state court in Minnesota which purported to bring claims belonging to the Company against the Company’s Board of Directors and various officers and former officers for alleged malfeasance in the management of the Company. The claims were based on substantially the same allegations as those underlying the securities class action litigation described above. The defendants (consisting of the Company’s Board of Directors and various officers and former officers) filed a motion to dismiss, and in June 2007 the state court granted the motion, thus dismissing the derivative case for failure of the complainant to make a demand on the Board. In September 2007, the plaintiff sent a shareholder demand letter to the Board. The Board considered the letter at its October 25, 2007 Board meeting and requested that the complainant provide it with details to substantiate the allegations. In June 2008, the complainant filed a derivative action against the defendants again. The court denied the defendants’ motion to dismiss concerning that complaint. To date, the complainant has not provided any material facts to support the allegations. The plaintiff filed an amended complaint on July 13, 2009 which contains many deficiencies and which is also in substantial conflict with the District Court’s ruling in the <i>Securities Class Action Litigation </i>above. The defendants intend to continue to vigorously defend against the claims raised in this action. The Company’s directors and officers liability insurance provides $75 million of insurance coverage for the Company, the officers and the directors, after a $15 million self-insured retention level has been reached.  <br /> <br style="font-size: 6pt" /> The Company is also involved in various other product liability lawsuits, claims and proceedings that arise in the ordinary course of business. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>Regulatory Matters</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The FDA inspected the Company’s manufacturing facility in Minnetonka, Minnesota at various times between December 8 and December 19, 2008. On December 19, 2008, the FDA issued a Form 483 identifying certain observed non-conformity with current Good Manufacturing Practice (cGMP) primarily related to the manufacture and assembly of the Safire<sup style="font-size: 85%; vertical-align: text-top">TM</sup> ablation catheter with a 4 mm or 5 mm non-irrigated tip. Following the receipt of the Form 483, the Company’s Atrial Fibrillation division provided written responses to the FDA detailing proposed corrective actions and immediately initiated efforts to address FDA’s observations of non-conformity. The Company subsequently received a warning letter dated April 17, 2009 from the FDA relating to these non-conformities with respect to this facility. </div>   </div>  <div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 6pt">The FDA inspected the Company’s Plano, Texas manufacturing facility at various times between March 5 and April 6, 2009. On April 6, 2009, the FDA issued a Form 483 identifying certain observed non-conformities with cGMP. Following the receipt of the Form 483, the Company’s Neuromodulation division provided written responses to the FDA detailing proposed corrective actions and immediately initiated efforts to address FDA’s observations of non-conformity. The Company subsequently received a warning letter dated June 26, 2009 from the FDA relating to these non-conformities with respect to its Neuromodulation division’s Plano, Texas and Hackettstown, New Jersey facilities. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">With respect to each of these warning letters, the FDA notes that it will not grant requests for exportation certificates to foreign governments or approve pre-market approval applications for Class III devices to which the quality system regulation deviations are reasonably related until the violations have been corrected. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Customer orders are not expected to be impacted while the Company works to resolve the FDA’s concerns. The Company takes these matters seriously and is working diligently to respond timely and fully to the FDA’s requests. While the Company believes the FDA’s concerns can be resolved without a material impact on the Company’s financial results, the FDA has recently been increasing its scrutiny of the medical device industry and the government should be expected to continue to scrutinize the industry closely with inspections, and possibly enforcement actions, by the FDA or other agencies. The Company is regularly monitoring, assessing and improving its internal compliance systems and procedures so that its activities will be consistent with applicable laws, regulations and requirements, including those of the FDA. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>Product Warranties</b>  <br /> <br style="font-size: 6pt" /> The Company offers a warranty on various products, the most significant of which relates to its ICDs and pacemakers. The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product is sold. Factors that affect the Company’s warranty liability include the number of units sold, historical and anticipated rates of warranty claims and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.  <br /> <br style="font-size: 6pt" /> Changes in the Company’s product warranty liability during the three and six months ended July 4, 2009 and June 28, 2008 were as follows (in thousands): </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">  <tr valign="bottom"> <td width="52%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 0px solid #000000"><b>Three Months Ended</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 0px solid #000000"><b>Six Months Ended</b></td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>July 4,</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>June 28,</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>July 4,</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>June 28,</b></td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"><b> </b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"><b>2009</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"><b>2008</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"><b>2009</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"><b>2008</b></td> </tr>   <tr style="font-size: 1px"> <td colspan="17" align="left" style="border-top: 2px solid #000000"> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Balance at beginning of period </div></td> <td> </td> <td align="right">$</td> <td align="right">16,335</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">17,238</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">15,724</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">16,691</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Warranty expense recognized </div></td> <td> </td> <td> </td> <td align="right">1,679</td> <td> </td> <td> </td> <td> </td> <td align="right">598</td> <td> </td> <td> </td> <td> </td> <td align="right">3,028</td> <td> </td> <td> </td> <td> </td> <td align="right">1,573</td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Warranty credits issued </div></td> <td> </td> <td nowrap="nowrap" align="right"> </td> <td align="right">(509</td> <td nowrap="nowrap">)</td> <td> </td> <td nowrap="nowrap" align="right"> </td> <td align="right">(560</td> <td nowrap="nowrap">)</td> <td> </td> <td nowrap="nowrap" align="right"> </td> <td align="right">(1,247</td> <td nowrap="nowrap">)</td> <td> </td> <td nowrap="nowrap" align="right"> </td> <td align="right">(988</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td colspan="17" align="left" style="border-top: 1px solid #000000"> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Balance at end of period </div></td> <td> </td> <td align="right">$</td> <td align="right">17,505</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">17,276</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">17,505</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">17,276</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="17" align="left" style="border-top: 2px solid #000000"> </td> </tr>  </table> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>Other Commitments</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">  The Company has certain contingent commitments to acquire various businesses involved in the distribution of the Company’s products and to pay other contingent acquisition consideration payments. While it is not certain if and/or when these payments will be made, as of July 4, 2009, the Company estimates it could be required to pay approximately $307 million in future periods to satisfy such commitments. Refer to Part II, Item 7, <i>Management’s Discussion and Analysis of Financial Condition and Results of Operations – Off-Balance Sheet Arrangements and Contractual Obligations </i>of the Company’s 2008 Annual Report on Form 10-K for additional information.   </div>   </div>  <div style="font-family: 'Times New Roman',Times,serif"> </div> </body> </html>

<html> <head></head> <body>  <div style="font-family: 'Times New Roman',Times,serif"> <div align="left"> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>NOTE 14 – SEGMENT AND GEOGRAPHIC INFORMATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"><b>Segment Information</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and implantable neurostimulation devices for the management of chronic pain and neurological disorders. The Company’s four operating segments are Cardiac Rhythm Management (CRM), Cardiovascular (CV), Atrial Fibrillation (AF) and Neuromodulation (NMD). Each operating segment focuses on developing and manufacturing products for its respective therapy area. The primary products produced by each operating segment are: CRM – ICDs and pacemakers; CV – vascular closure devices, heart valve replacement and repair products and pressure measurement guidewires; AF – electrophysiology introducers and catheters, advanced cardiac mapping and navigation systems and ablation systems; and NMD – neurostimulation devices. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company has aggregated the four operating segments into two reportable segments based upon their similar operational and economic characteristics: CRM/NMD and CV/AF. Net sales of the Company’s reportable segments include end-customer revenue from the sale of products they each develop and manufacture or distribute. The costs included in each of the reportable segments’ operating results include the direct costs of the products sold to end-customers and operating expenses managed by each reportable segment. Certain operating expenses managed by the Company’s selling and corporate functions, including all stock-based compensation expense, are not included in the reportable segments’ operating profit. As a result, reportable segment operating profit is not representative of the operating profit of the products in these reportable segments. Additionally, certain assets are managed by the Company’s selling and corporate functions, principally including end-customer receivables, inventory, corporate cash and cash equivalents and deferred income taxes. For management reporting purposes, the Company does not compile capital expenditures by reportable segment and, therefore, this information has not been presented as it is impracticable to do so. </div>   </div>  <div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following table presents net sales and operating profit by reportable segment (in thousands): </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">  <tr valign="bottom"> <td width="52%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>CRM/NMD</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>CV/AF</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>Other</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>Total</b></td> </tr>   <tr style="font-size: 1px"> <td colspan="17" align="left" style="border-top: 2px solid #000000"> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><i>Three Months ended July 4, 2009:</i> </div></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Net sales </div></td> <td> </td> <td align="right">$</td> <td align="right">784,913</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">399,499</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">—</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">1,184,412</td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Operating profit </div></td> <td> </td> <td> </td> <td align="right">486,024</td> <td> </td> <td> </td> <td> </td> <td align="right">211,987</td> <td> </td> <td> </td> <td nowrap="nowrap" align="right"> </td> <td align="right">(393,364</td> <td nowrap="nowrap">)</td> <td> </td> <td> </td> <td align="right">304,647</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="17" align="left" style="border-top: 1px solid #000000"> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><i>Three Months ended June 28, 2008:</i> </div></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Net sales </div></td> <td> </td> <td align="right">$</td> <td align="right">772,404</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">363,356</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">—</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">1,135,760</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Operating profit </div></td> <td> </td> <td> </td> <td align="right">479,399</td> <td> </td> <td> </td> <td> </td> <td align="right">194,379</td> <td> </td> <td> </td> <td nowrap="nowrap" align="right"> </td> <td align="right">(380,425</td> <td nowrap="nowrap">)</td> <td> </td> <td> </td> <td align="right">293,353</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="17" align="left" style="border-top: 2px solid #000000"> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><i>Six Months ended July 4, 2009:</i> </div></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Net sales </div></td> <td> </td> <td align="right">$</td> <td align="right">1,533,681</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">784,524</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">—</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">2,318,205</td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Operating profit </div></td> <td> </td> <td> </td> <td align="right">947,054</td> <td> </td> <td> </td> <td> </td> <td align="right">402,872</td> <td> </td> <td> </td> <td nowrap="nowrap" align="right"> </td> <td align="right">(763,007</td> <td nowrap="nowrap">)</td> <td> </td> <td> </td> <td align="right">586,919</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="17" align="left" style="border-top: 1px solid #000000"> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><i>Six Months ended June 28, 2008:</i> </div></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Net sales </div></td> <td> </td> <td align="right">$</td> <td align="right">1,455,716</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">690,782</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">—</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">2,146,498</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Operating profit </div></td> <td> </td> <td> </td> <td align="right">899,673</td> <td> </td> <td> </td> <td> </td> <td align="right">368,297</td> <td> </td> <td> </td> <td nowrap="nowrap" align="right"> </td> <td align="right">(715,117</td> <td nowrap="nowrap">)</td> <td> </td> <td> </td> <td align="right">552,853</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="17" align="left" style="border-top: 2px solid #000000"> </td> </tr>  </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following table presents the Company’s total assets by reportable segment (in thousands): </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">  <tr valign="bottom"> <td width="76%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Total Assets</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>July 4, 2009</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>January 3, 2009</b></td> </tr>   <tr style="font-size: 1px"> <td colspan="9" align="left" style="border-top: 2px solid #000000"> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">CRM/NMD </div></td> <td> </td> <td align="right">$</td> <td align="right">2,071,308</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">2,018,478</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">CV/AF </div></td> <td> </td> <td> </td> <td align="right">1,318,204</td> <td> </td> <td> </td> <td> </td> <td align="right">1,267,290</td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other </div></td> <td> </td> <td> </td> <td align="right">2,974,311</td> <td> </td> <td> </td> <td> </td> <td align="right">2,436,736</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="9" align="left" style="border-top: 1px solid #000000"> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td align="right">$</td> <td align="right">6,363,823</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">5,722,504</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="9" align="left" style="border-top: 2px solid #000000"> </td> </tr>  </table> </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>Geographic Information</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The following table presents net sales by geographic location of the customer (in thousands): </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">  <tr valign="bottom"> <td width="52%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 0px solid #000000"><b>Three Months Ended</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 0px solid #000000"><b>Six Months Ended</b></td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>July 4,</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>June 28,</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>July 4,</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>June 28,</b></td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Net Sales</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>2009</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>2008</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>2009</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>2008</b></td> </tr>   <tr style="font-size: 1px"> <td colspan="17" align="left" style="border-top: 2px solid #000000"> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">United States </div></td> <td> </td> <td align="right">$</td> <td align="right">630,658</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">582,548</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">1,250,999</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">1,120,010</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">International </div></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Europe </div></td> <td> </td> <td> </td> <td align="right">299,552</td> <td> </td> <td> </td> <td> </td> <td align="right">316,733</td> <td> </td> <td> </td> <td> </td> <td align="right">584,320</td> <td> </td> <td> </td> <td> </td> <td align="right">586,878</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Japan </div></td> <td> </td> <td> </td> <td align="right">118,756</td> <td> </td> <td> </td> <td> </td> <td align="right">99,485</td> <td> </td> <td> </td> <td> </td> <td align="right">230,908</td> <td> </td> <td> </td> <td> </td> <td align="right">185,289</td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Asia Pacific </div></td> <td> </td> <td> </td> <td align="right">65,027</td> <td> </td> <td> </td> <td> </td> <td align="right">63,153</td> <td> </td> <td> </td> <td> </td> <td align="right">118,601</td> <td> </td> <td> </td> <td> </td> <td align="right">116,193</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Other (a) </div></td> <td> </td> <td> </td> <td align="right">70,419</td> <td> </td> <td> </td> <td> </td> <td align="right">73,841</td> <td> </td> <td> </td> <td> </td> <td align="right">133,377</td> <td> </td> <td> </td> <td> </td> <td align="right">138,128</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="17" align="left" style="border-top: 1px solid #000000"> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td> </td> <td align="right">553,754</td> <td> </td> <td> </td> <td> </td> <td align="right">553,212</td> <td> </td> <td> </td> <td> </td> <td align="right">1,067,206</td> <td> </td> <td> </td> <td> </td> <td align="right">1,026,488</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="17" align="left" style="border-top: 1px solid #000000"> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td align="right">$</td> <td align="right">1,184,412</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">1,135,760</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">2,318,205</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">2,146,498</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="17" align="left" style="border-top: 2px solid #000000"> </td> </tr>  </table> </div> <div style="margin-top: 6pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="1%" nowrap="nowrap" align="left">(a)</td> <td width="1%"> </td> <td>No one geographic market is greater than 5% of consolidated net sales.</td> </tr> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The amounts for long-lived assets by significant geographic market include net property, plant and equipment by physical location of the asset. The prior period has been reclassified to conform to the current year presentation. The following table presents long-lived assets by geographic location (in thousands): </div>   </div>  <div style="font-family: 'Times New Roman',Times,serif"> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">  <tr valign="bottom"> <td width="76%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> <td width="5%"> </td> <td width="3%"> </td> <td width="1%"> </td> <td width="3%"> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left"><b>Long-Lived Assets</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>July 4, 2009</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="3"><b>January 3, 2009</b></td> </tr>   <tr style="font-size: 1px"> <td colspan="9" align="left" style="border-top: 2px solid #000000"> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">United States </div></td> <td> </td> <td align="right">$</td> <td align="right">856,053</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">775,205</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">International </div></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Europe </div></td> <td> </td> <td> </td> <td align="right">87,991</td> <td> </td> <td> </td> <td> </td> <td align="right">84,266</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Japan </div></td> <td> </td> <td> </td> <td align="right">14,563</td> <td> </td> <td> </td> <td> </td> <td align="right">16,001</td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Asia Pacific </div></td> <td> </td> <td> </td> <td align="right">19,760</td> <td> </td> <td> </td> <td> </td> <td align="right">17,087</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Other </div></td> <td> </td> <td> </td> <td align="right">92,972</td> <td> </td> <td> </td> <td> </td> <td align="right">87,617</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="9" align="left" style="border-top: 1px solid #000000"> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td> </td> <td align="right">215,286</td> <td> </td> <td> </td> <td> </td> <td align="right">204,971</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="9" align="left" style="border-top: 1px solid #000000"> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td align="right">$</td> <td align="right">1,071,339</td> <td> </td> <td> </td> <td align="right">$</td> <td align="right">980,176</td> <td> </td> </tr> <tr style="font-size: 1px"> <td colspan="9" align="left" style="border-top: 2px solid #000000"> </td> </tr>  </table> </div> <div align="left"> </div> </div> </body> </html>

false --01-02 2009-07-04 10-Q 0000203077 347981258 Yes Large Accelerated Filer 13700000000 St. Jude Medical, Inc. No Yes 2662265000 2668671000

238310000

229243000

1101258000

1177067000

17608000

18357000

695803000

762109000

6136000

6690000

-411000

-1023000

35958000

219041000

302675000

37408000

29531000

28971000

30942000

26008000

5722504000

6363823000

2080063000

2623813000

389094000

397481000

136443000

486569000

8387000

350126000

0.1

500000000

345332272

347640007

345332272

347640007

34533000

34764000

548178000

287691000

600039000

305544000

154925000

82421000

154005000

80316000

4862000

13415000

137042000

135454000

112231000

126738000

62708000

71413000

1.08

0.57

1.21

0.63

1.06

0.55

1.2

0.63

11302000

2197000

297287000

284375000

18543000

12866000

-18543000

-12866000

1984566000

1985966000

1598320000

848069000

1718166000

878868000

524406000

275333000

574646000

299686000

20406000

-34076000

-106533000

-68780000

-9666000

17427000

-16125000

-64864000

-14507000

-41360000

493535000

474256000

546499000

620117000

2486598000

2585465000

5722504000

6363823000

1028524000

1243318000

75518000

324525000

1126084000

961022000

-218194000

155679000

-165020000

-166211000

380299000

358461000

369481000

192912000

420641000

219370000

-28447000

-18020000

-12273000

-4961000

552853000

293353000

586919000

304647000

158821000

204606000

184164000

208449000

399801000

386818000

219759000

254387000

22011000

-1330000

300000000

6359000

9065000

136650000

158476000

25000000

6687000000

63263000

39588000

1675979000

1833448000

980176000

1071339000

6583775000

262090000

138455000

282403000

143052000

2977630000

3398271000

2146498000

1135760000

2318205000

1184412000

783377000

416261000

848844000

431169000

24800000

27980000

3235906000

3778358000

350112000

348269000

350213000

350620000

342178000

340699000

346308000

346767000